A case of successful treatment of pancreatic cancer

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: Treatment of pancreatic cancer presents significant difficulties due to the aggressive course of the disease and the extremely low sensitivity of the tumor to standard chemotherapy. In recent years, researchers have increasingly considered the possibility of using immunotherapeutic drugs capable of potentiating the effectiveness of cytostatic therapy as part of antitumor treatment of such patients. They draw particular attention to the combination of interferon-γ and recombinant tumor necrosis factor thymosin-α-1, capable of activating an antitumor immune response, stimulating apoptosis of tumor cells, having a direct antiproliferative effect, causing destruction of neoplasm vessels, stimulating necrosis of tumor tissue.

DESCRIPTION: The patient with stage IV pancreatic head cancer underwent 13 courses of FOLFIRINOX therapy. Treatment was terminated because of increasing toxicity. According to computed tomography, disease progression was detected. The patient referred to cytokinogenetic therapy. After completion of the fourth treatment course, the partial response was seen on computed tomography scan. The TNFα level and the Karnofsky score both grew during the therapy.

CONCLUSION: Cytokinogenetic therapy made it possible to improve the patient’s quality of life, to stabilize his general condition and functional activity, to achieve partial regression of the tumor, and to increase the chances of survival.

作者简介

Andrey Ilyushin

OncoCare Clinic 308

Email: onkolog_77@mail.ru
ORCID iD: 0009-0000-5065-4342

MD, Cand. Sci. (Med.)

俄罗斯联邦, 4A Fadeeva street, 125047 Moscow

Amir Ben Ammar

OncoCare Clinic 308

编辑信件的主要联系方式.
Email: amirbenammar94095@gmail.com
ORCID iD: 0000-0001-9239-2539

mammologist, oncologist, surgeon

俄罗斯联邦, 4A Fadeeva street, 125047 Moscow

参考

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66(1):7–30. doi: 10.3322/caac.21332
  2. Okeanov AE, Moiseev PI, Levin LF, et al. Cancer in Belarus: figures and facts. Analysis of data from the Belarusian Cancer Registry for 2009-2018. Sukonko OG, editor. Minsk: National Library of Belarus, 2019. (In Russ)
  3. Shchastny AT, Lud NG, Sobol VN, et al. The analysis of the patients’ survival rate in the comprehensive treatment for cancer of the head of the pancreas. Vestnik of Vitebsk State Medical University. 2020;5:66–71. (In Russ) doi: 10.22263/2312-4156.2020.5.66
  4. Foltz EE. Pancreatic cancer. Bulletin of Medical Internet Conferences. 2019;9(3):146–151. (In Russ)
  5. Shmak AI, Reutovich MJu, Yakoubovich IA. Results of complex treatment of resectable pancreatic head cancer. Oncological Journal. 2014;8(3):60–65. (In Russ)
  6. Imaoka H, Ikeda M, Maehara K, et al. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. BMC Cancer. 2020;20(1). doi: 10.1186/s12885-020-07462-4
  7. Korentzelos D, Wells A, Clark AM. Interferon-γ Increases Sensitivity to Chemotherapy and Provides Immunotherapy Targets in Models of Metastatic Castration-Resistant Prostate Cancer. Scientific Reports. 2022;12(1). doi: 10.1038/s41598-022-10724-9
  8. Zhang M, Huang L, Ding G, et al. Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2020;8(1):e000308. doi: 10.1136/jitc-2019-000308
  9. Ardzha AYu, Nepomnyashchaya EM, Zlatnik EYu, et al. Characteristics of expression of some immunohistochemical markers in patients with stage IIIC-IV ovarian cancer as a criterion of effectiveness of chemoimmunotherapy. Nauka Molodykh (Eruditio Juvenium). 2020;8(4):582–590. (In Russ) doi: 10.23888/HMJ202084582-590
  10. Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research. 2020;8(1). doi: 10.1186/s40364-020-00228-x
  11. Wang L, Wang Y, Song Z, et al. Deficiency of Interferon-Gamma or Its Receptor Promotes Colorectal Cancer Development. Journal of Interferon & Cytokine Research. 2015;35(4):273–280. doi: 10.1089/jir.2014.0132
  12. Wang QS, Shen SQ, Sun HW, et al. Interferon-gamma induces autophagy-associated apoptosis through in-duction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells. Biochemical and Biophysical Research Communications. 2018;498(4):1058–1065. doi: 10.1016/j.bbrc.2018.03.118
  13. Kammertoens T, Friese C, Arina A, et al. Tumor ischaemia by interferon-γ resembles physiological blood vessel regression. Nature. 2017;545(7652):98–102. doi: 10.1038/nature22311
  14. Kadagidze ZG, Slavina EG, Chertkova AI. Interferon-gamma in oncology. Farmateka. 2013;17(270):40–44. (In Russ)
  15. Bryuzgin VV, Platinskij LV. The role of cytokines in the chemotherapy of malignant tumors: the practice of cytokines Refnot® and Ingaron® administration in advanced cancer with multiple metastases. Journal of Modern Oncology. 2014;16(1):70–75. (In Russ)
  16. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences. 1975;72(9):3666–

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Computed tomography from 03.12.2022 (before the start of cytokinogenetic therapy). Formation of the head of the pancreas after 13 courses of polychemotherapy according to the FOLFIRINOX regimen.

下载 (215KB)
索引源数据
3. Fig. 2. Computed tomography from 26.02.2023. Formation of the head of the pancreas after three courses of cytokinogenetic therapy.

下载 (193KB)
索引源数据

版权所有 © Eco-Vector, 2022


 


##common.cookie##